Lederle Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 08-12-2024
- Paid Up Capital ₹ 1.25 Cr
as on 08-12-2024
- Company Age 17 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.25 Cr
as on 08-12-2024
- Revenue 34.26%
(FY 2022)
- Profit 115.56%
(FY 2022)
- Ebitda 125.41%
(FY 2022)
- Net Worth 0.50%
(FY 2022)
- Total Assets 57.58%
(FY 2022)
About Lederle Pharma
The Corporate was formerly known as Lederle Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.25 Cr.
The company currently has active open charges totaling ₹1.25 Cr.
Sanjay Surana, Mehul Surana, and Ajay Surana serve as directors at the Company.
- CIN/LLPIN
U24233DL2007PLC168221
- Company No.
168221
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Sep 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lederle Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Surana  | Director | 26-Oct-2007 | Current |
| Mehul Surana | Director | 12-Jul-2021 | Current |
| Ajay Surana | Director | 01-Jul-2017 | Current |
Financial Performance and Corporate Structure Insights of Lederle Pharma.
Lederle Pharma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 34.26% increase. The company also saw a substantial improvement in profitability, with a 115.56% increase in profit. The company's net worth moved up by a moderate rise of 0.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lederle Pharma?
In 2022, Lederle Pharma had a promoter holding of 35.18% and a public holding of 64.82%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jas Leasing And Property Developers Limited.Active 35 years 4 monthsSanjay Surana and Ajay Surana are mutual person
- Surana Buildcon Private LimitedActive 38 years 7 months
Sanjay Surana and Mehul Surana are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Nainital Bank Limited Creation Date: 14 Jun 2010 | ₹1.25 Cr | Open |
How Many Employees Work at Lederle Pharma?
Unlock and access historical data on people associated with Lederle Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lederle Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lederle Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
